Publications
Chosen filters:
Chosen filters:
Matérialiser sa noblesse sur la frontière des anciens Pays-Bas avec la France : le patrimoine architectural de Charles de Croÿ, prince de Chimay et duc d’Aarschot (1560–1612) Vrije Universiteit Brussel
This chapter is part of a volume that studies the role of the Croÿ family in the religious and political conflicts of the sixteenth century, specifically in the border region between France and the Habsburg Low Countries. Our contribution focuses on Charles of Croÿ (1560–1612), Prince of Chimay and Duke of Aarschot, who was one of the most prominent noblemen in the Low Countries as well as a distinguished art collector and architectural patron. ...
"Hamlet without the Prince." Charles Taylor over realisme, pluralisme en transcendentie. KU Leuven
De opzet van dit doctoraat is tweeledig. Eerst en vooral is het bedoeld als een monografie over Charles Taylor. Daarbij gaat het niet om een klassieke leven en werk. Dat leven is immers tot op heden onvoltooid, en ook het oeuvre van Taylor, hoe omvangrijk ook, wacht nog steeds op een orgelpunt. Omdat een exhaustieve monografie bij voorbaat uitgesloten was, leek een thematische benadering de aangewezen weg. De behandelde themas vallen uiteen in ...
Hierarchy and the Nature of Information Vrije Universiteit Brussel
We address the nature of information from a systemic structural point of view. Starting from
the Natural hierarchy of living systems, we elucidate its decomposition into two partial hierarchies
associated with its extant levels and inter-level regions, respectively. External observation of a
hierarchical system involves the generation of approximate hyperscalar representations of these two
partials, which then reintegrate to ...
the Natural hierarchy of living systems, we elucidate its decomposition into two partial hierarchies
associated with its extant levels and inter-level regions, respectively. External observation of a
hierarchical system involves the generation of approximate hyperscalar representations of these two
partials, which then reintegrate to ...
A Peircean framework for analyzing subjectivity in film University of Antwerp
The goal of this article is to offer a new model for the study of ocularization in film grounded in the semiotic pragmatism of Charles Sanders Peirce. We first present a literature overview addressing the state of research regarding the theorization of ocularization in film studies. Second, we discuss Peirce's three universal categories (Firstness, Secondness, and Thirdness) on which our model will be based. Third, we argue how the theme of ...
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome University of Antwerp KU Leuven
BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C ...
Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial University of Antwerp KU Leuven
BACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. OBJECTIVES This pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment ...
Alirocumab reduces total hospitalizations and increases days alive and out of hospital in the ODYSSEY OUTCOMES trial University of Antwerp KU Leuven
Background: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18924 patients. Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic ...